No Cancer Foundation is a humanitarian organization that works international "for" health, peace, social justice and human rights, "against" industrial mass poisoning, cancer and other poisoning diseases. Taking into account the continuing unconstitutional, on corruption and abuse of power based terror on No Cancer Foundation and its partners, we are unable to answer all e-mails as long as our Constitution and rule of law is hostage. Therefore the entire content of the No Cancer Foundation website is transferred as research achive to the 'The European Greens' political movement. The content remains to represent No Cancer Foundation and partners as official juridical foundation for existing and further legal proceedings. No Cancer Foundation plenipotentiary jurist, by European Commission recognized European safety manager, A.M.L. van Rooij is disabled in his legal function and right to existence by means of corruption and abuse of power,  which is called fascism. Let's end mass poisoning and related cancer pandemic once and for all! Support us and let them know!

FLARAXIN
Clinical trial & scientific facts and figures on Flaraxin

III-rd AND IV-th STAGE OF MALIGNANT NEOPLASM TREATMENT

FLARAXIN-infusion is a non-toxic anti-cancer, anti-viral herbal medicine, interferogen, stimulates tumor necrosis factor, destroys tumor tissue and is working as a protector of healthy cells in case of chemotherapy. Immunomodulator and antioxidant, prevents metastatic spreading and relapse and is reducing concentration of toxins and common intoxication in the body, are safe for the application and it does not have any side effects, reduces the concentration of oncofetal proteins in the body.  


Clinical trials on Flaraxin translated and notarized confirmed by oath.


In many cases it gives regression of the tumor and destruction of metastases and metastatic process in all organs. Flaraxin prevents recurrence of the disease.

° Flaraxin is compatible with other medicines, except iron containing medicines (flaraxin can bounds to Fe, and it will give neutralization). In combination treatment with the Chemotherapy and the Gama-ray therapy, flaraxin will multiply action of Chemotherapy and Gamma-ray on onco-cells and is highly reducing their toxic damage of healthy (normal) cells.

° Flaraxin is efficient on I-IV stages of cancer process of malignant and non-malignant tumors (neoplasms): of brain (glioma, ependymoma, oligodendroglioma etc.); skin cancer (melanoma, basalioma etc.); lung cancer (sarcoma, adenocarcinoma and etc.); mammary cancer; cancer of the pharynx and larynx; esophageal cancer, stomach cancer (adenocarcinoma, sarcoma), colon cancer, kidney cancer, bladder cancer, prostate cancer, cancer of female reproductive organs (uterus cancer, cervix cancer, ovaries cancer); lymphogranulomathosis, blood diseases, with benign tumors (uterine fibroids, polycystosis of ovaries, mastitis, adenoma of the prostate, polyps of various organs, etc.);

English subtitle

The features of therapy with FLARAXIN are:

° Good tolerability of medication FLARAXIN;

° No side-effects with high anti-tumor activity;

° High possibility to bring the tumor into complete regression;

° Prevention of recurrence of the disease, destruction and prevention of metastasis;

° The absence of toxic effects, because of the high selectivity of FLARAXIN.

FLARAXIN might be used by the patients 

° Do not subjected to traditional treatments (which are not able to pass the surgery, chemotherapy, X-ray or Gamma therapy);

° That are undergoing chemotherapy or radiotherapy (FLARAXIN compatible with surgery, chemotherapy, X-ray or Gamma therapy);

° With an inoperable form of the disease;

° That do not subjected to radiation or gamma therapy;

° With severe allergic reaction to the administration of chemotherapeutic medications;

° Weakened.

Pharmacological action of FLARAXIN 

° Bounds with oncofetal proteins and destroys them;

° Increases the quantity of natural killers (NK-cells), T-lymphocytes;

° Stimulates the production of endogenic interferon and tumor necrosis factor;

° Normalize immunological background (removes immune disorders);

° Normalizes the ratio of immune cells CD4/CD8 (helpers - suppressors).


FLARAXIN is efficient for: 

° Cerebrum (Brain) cancer (glioma, ependymoma, oligodendroglioma, nervinoma etc.);

° Skin cancer (melanoma, melanoblastoma, skin melanoma treatment, basalioma etc.);
Lung cancer; (

° Lung cancer; (treatment of lung cancer on last stage);

° Breast cancer;

° Female sexual sphere cancer (uterus cancer, cervix cancer, ovaries cancer);

° Stomach cancer;

° Colon cancer;

° Colorectal cancer (adenocarcinoma, carcinoma and etc.);

° Kidneys cancer (adenocarcinoma, carcinoma and etc.);

° Bladder cancer;

° Pancreas cancer;

° Prostate cancer (adenoma, treatment of the prostate cancer);

° Cancer of the pharynx and larynx;

° Esophageal cancer;

° Mediastinal cancer (tumors of the mediastinum);

° Under non-malignant neoplasm of various localities (fibroids, myoma and etc. ).

° Neoplastic diseases of the blood system;

° Tumoral diseases of lymphatic system; 

English subtitle

PATENT ON AN INVENTION #25833

A remedy for melanoblastoma treatment

Athor: KULIK IVAN ONISIMOVICH (UA)

Issued according to law of Ukraine "On Protection of Rights to Inventions and Utility Models"

Registered in the State Register of Patents of Ukraine for inventions 26 February 1999.

Head of the State Department of Intellectual Property

° Ministry of Education and Science of Ukraine

° State Department of Intellectual Property

https://docs.google.com/viewer?a=v&pid=sites&srcid=ZGVmYXVsdGRvbWFpbnx0aGVldXJvcGVhbmdyZWVuc3xneDo3YTQ1YTZhMGU2YWY1ODA3

DESCRIPTION OF THE PATENT № 25833

The invention relates to a herbal medicines and intended for the treatment of melanomoblastoma (cancer).

The Aim of the invention is to find new medicine FLARAXIN with higher antitumor activity and low toxicity.

EXAMPLE 1

A mixture of tannin and potassium iodide at a ratio of 3:1, lyophilized, packaged in 20ml sterile vials and hermetically sealed.

During treatment of patients with melanomoblastoms by new medicine that were dissolved in 5% glucose solution in the volume of 20ml and by 20 ml syringe were injected intravenously once a day. The course of treatment were 15 – 30 days intravenous administrations.

The effectiveness of the proposed remedy in comparison with Decarbonize and Polychemotherapy is illustrated below in a data table.

As can be seen from the table, FLARAXIN treatment efficiency is 90%, while Dacarbazine only 15-20% and Chemotherapy gives only 20 - 30%. Furthermore, Chemotherapeutic antineoplastic medicines all without exception, have a high degree of toxicity, resulting in the damage of organs, not only the tumor containing organs, but the complex system damage that are not affected by the tumor. High toxicity limits the assignment of chemotherapy in particular, it is contra-indicated to the patients in terminal stages of the disease with neoplastic process. One persistent pathologies which limits the use of chemotherapy, damage of leukocyte blood sprout (germ) that causes persistent leukopenia.

The drug FLARAXIN refers to low-toxic compounds. Its use for the treatment of melanomoblastoms showed that it acts selectively on tumor process and has no effects on organs and systems. This allows applying FLARAXIN at different stages of the cancer disease, including the terminal stages.

Estimation of efficiency and toxicness of FLARAXIN with traditional preparations of chemotherapy for the melanoblastomax/ treatment.

PATENT ON AN INVENTION #22012

https://sites.google.com/site/bestandenfotos/flaraxin/Screenshot_143.png

Efficiency of flaraxin application on different oncological diseases (Click on doc)

FLARAXIN is not enough efficient in case of the high liver damage (more than 50%), in case of the bone cancer.


Clinical use of FLARAXIN expedient in the following cases 

1.    FLARAXIN should be used in patients with precancerous proliferative processes, as well as in patients with minimal tumor process, after radical surgical treatment when it is necessary to restore anti-tumor resistance of the organism and its homeostatic mechanisms;

2.    The treatment by FLARAXIN could be as a base or be as a background, precede chemotherapy and radiotherapy, besides it may be used in between traditional treatment cycles, and as a medication for stabilization of achieved results in the classic anticancer therapy. It is possible due to its minimal toxicity and selective action on tumor tissue;

3.    Patients with advanced neoplastic process could use FLARAXIN in the complex chemotherapy, radiotherapy, by using its specific anti-tumor activity and anti-viral, immune-stimulating properties;

4.    In case of impossibility of surgery, chemo- or radiotherapy, FLARAXIN should be used independently.

FLARAXIN is compatible with many antineoplastic medications except metal containing because it could give complex formations with iron due to his chemical properties.

FLARAXIN is reducing 

° Cardio toxicity, specified by lypooxigenesis activation, typical to antibiotics of antracyclic group;

° Neurotoxicity -  like preparations of vinca-class (Vincristine, Vinblastine);

° Para pyramidal disorders and syndrome of “orthostatic hypotension” like Fluorouracil;

° Myelotoxic effect and immune depression - like alkylating preparations, etc.


FLARAXIN should be included in the next treatment schemes of patients with cancer:

Known methods of cancer treatment (chemotherapy, radiation, surgery) are accompanied by high immune suppression, which strongly inhibits the function of the immune system, closing the vicious circle of cancer process.

Chemotherapy involves the use of drugs with a variety of reactive groups, that are denaturing proteins not only the oncological cells but also normal cells, which explains their high toxicity to the body.

FLARAXIN interacts only with tumor cells, causing their death, with absolutely no effect on the blood, respiratory, digestive and excretory system, central nervous system, skin and etc. As a powerful Immunomodulator it does not suppress the immune system, and increases the level of functional activity of immune system.

In the case of the FLARAXIN appointment before chemotherapy 

It is necessary to consider some of FLARAXIN features. Under the influence of FLARAXIN tumor cells become more vulnerable with respect to the factors of natural anti-tumor immunity and for the anti-tumor cytotoxic drugs. In this case FLARAXIN works as a protector of normal cells. Therefore, for a more effective treatment it is needed to prepare the original immuno-biochemical parameters of patients by FLARAXIN application, especially before start of chemotherapy.

Flaraxin should be prescribed under the low level of cytotoxic activity of natural killers (lower 40% - necessarily, 50-55% - preferably); at the presence of the initial nonprotein SH groups in the blood serum (spontaneous disproteinemia with autoimmune aggression) as well as in case of violation of redox (SH-SS) potential of serum proteins.

Often, all these violations are combined with each other. If the designated 8 injections of FLARAXIN normalized existing violations noted above, it is possible to begin chemotherapy. If on the background of positive dynamics after 8 injections have not yet reached the optimal immune-biochemical parameters, there is reason to assign additional 8 injections of FLARAXIN.

If it is impossible to carry out at least one of these immuno-biochemical tests, you can focus on the clinical picture of the treatment course of the disease. With a marked subjective improvement after first 8 injections of FLARAXIN, 8 more injections can be repeated.

It is impossible to continue FLARAXIN injections in case of individual intolerance to the medication. In such cases, the treatment scheme of the patient it is necessary to use antihistamine medication that is reducing autoimmune reaction of the body (Kenalog, Tavegil, Clemastine, Suprastinum etc.), or to provide few courses of plasmapheresis.

In the case of the FLARAXIN appointment before chemotherapy 

It is necessary to consider some of FLARAXIN features. Under the influence of FLARAXIN tumor cells become more vulnerable with respect to the factors of natural anti-tumor immunity and for the anti-tumor cytotoxic drugs. In this case FLARAXIN works as a protector of normal cells. Therefore, for a more effective treatment it is needed to prepare the original immuno-biochemical parameters of patients by FLARAXIN application, especially before start of chemotherapy.

Flaraxin should be prescribed under the low level of cytotoxic activity of natural killers (lower 40% - necessarily, 50-55% - preferably); at the presence of the initial nonprotein SH groups in the blood serum (spontaneous disproteinemia with autoimmune aggression) as well as in case of violation of redox (SH-SS) potential of serum proteins.

Often, all these violations are combined with each other. If the designated 8 injections of FLARAXIN normalized existing violations noted above, it is possible to begin chemotherapy. If on the background of positive dynamics after 8 injections have not yet reached the optimal immune-biochemical parameters, there is reason to assign additional 8 injections of FLARAXIN.

If it is impossible to carry out at least one of these immuno-biochemical tests, you can focus on the clinical picture of the treatment course of the disease. With a marked subjective improvement after first 8 injections of FLARAXIN, 8 more injections can be repeated.

It is impossible to continue FLARAXIN injections in case of individual intolerance to the medication. In such cases, the treatment scheme of the patient it is necessary to use antihistamine medication that is reducing autoimmune reaction of the body (Kenalog, Tavegil, Clemastine, Suprastinum etc.), or to provide few courses of plasmapheresis.


In the appointment of FLARAXIN after chemotherapy 

FLARAXIN treatment should be administered immediately after the end of chemotherapy, especially if a reduction in the immune - biochemical parameters happened. If patient is planning to the repeat course of chemotherapy in the future, than the treatment of FLARAXIN should be prolonged till the maximum improvements of the immune- biochemical parameters. One or two FLARAXIN courses in this case are dependent on the patient's biochemical parameters that were after chemotherapy. Cancer - is immunological problem which is based on the formation of antibodies in response to complex antigens of onco associating proteins and the medical agents.

If the immuno-biochemical indicators are reduced, then the use of plasmapheresis is an important component of medical therapy and its appointment is desirable after multiple courses of chemotherapy. (As alternative of plasmapheresis it could be the application of detoxification therapy). In this case the most informative indicator is to identify the initial non-protein SH-groups in the blood serum. Their appearance indicates the necessity to use plasmapheresis.

The use of the FLARAXIN, between courses of chemotherapy, could replace the function of plasmapheresis. Because the FLARAXIN has the ability to bind with immune complexes. If the combined use of chemotherapy and FLARAXIN still gives a negative immuno - biochemical parameters (especially the non-protein - SH groups), then the use of plasmapheresis is necessary. Number of plasmapheresis sessions could varied in dependence to the immunological disorders (control is a disappearance of SH -groups). Thus, for example, fractional plasmapheresis is necessary from 5 to 10 sessions with the cleaning (during each session) up to 500 ml of blood.

The appointment of FLARAXIN enhances the effect of chemotherapy and if tolerability of the used medications is good, than reduction of their dosage is not advisable. The combination of chemotherapy and FLARAXIN in reduced dosages is advisable in patients with underlying diseases that give difficulties to do a massive chemotherapy. In severe cases of patients where  FLARAXIN were assigned, it is necessary to include in the treatment scheme the chemotherapy medication in smaller doses ( 1/5-1/10 of normal dose) in order to strengthen the impact of oncolytic action of FLARAXIN. It is desirable to appoint the chemotherapy medication that is not previously prescribed to this patient.

The duration of combined application of FLARAXIN and chemotherapy should be determined by the clinical picture and immuno-biochemical parameters of the patient. If each course is accompanied by a normalization of the latter, than prolongation of the combined application of chemotherapy and FLARAXIN is necessary. The ideal scheme can be considered as a 3-4 courses of FLARAXIN additionally to chemotherapy and 1-2 courses of FLARAXIN in the next year, after the end of chemotherapy.

It is also advisable to prescribe FLARAXIN during the dispensary observation, in case of risk factors observation (stresses, reduced immune biochemical parameters, etc.).

In the intervals between chemotherapy when it is impossible to apply FLARAXIN, the prescription of herbal medications FITOMAX is advisable. Combined their use is justified in those cases where it is supposed to do the 1st massive chemotherapy course.

Important 

It is noted that the administration of medications containing plant polyphenols and dietary supplements with a high content of bioflavonoids (milk thistle, hellebore, Viola tricolor, etc.) have a negative impact on the therapeutic effect of FLARAXIN (observations are available). It is likely that in this case plays a role the degree of polyphenol compounds chemical reaction with other components (e.g., glycosylation). 

The Clinical trials (studies) proved the high efficacy of FLARAXIN in the preoperative period.

Firstly, there is a significant reduction in tumor nodules, which greatly simplifies the technique of surgical intervention; secondly, FLARAXIN has strong immunomodulatory and interferonogene properties and it allows accomplish surgical intervention on a more favorable immunologic background. Thus, clinically proved is the surgery with preliminary conduction of 1-2 therapy courses of FLARAXIN.

Because of the high antimetastatic activity of FLARAXIN, it is advisable to carry out the treatment in the postoperative period (1-2 courses of FLARAXIN), and also as a prophylactics before application of chemotherapy medications with aim to reduce negative impact on normal cells.

During radiation exposure on tumor nodes we recommended the application of polyphenolic compounds of herbal origin contained in the tablets of FITOMAX series, and after end of radiation course the application of FLARAXIN intravenously. Number of FLARAXIN courses can vary widely and depends on the dynamics of cancer process and general condition of the patient.

In cases where the use of chemotherapeutic medicaments does not give positive results the application of FLARAXIN is prescribed.

The clinical trials proved a positive impact of FLARAXIN on patients, which is manifested in the improvement of their general condition, the disappearance or reduction of tumor nodules and pain, increase in the vitality and physical activity.

FLARAXIN – QUESTIONS AND ANSWERS 

Head of the Laboratory of Pathomorphology and preservation of donor tissue. State Institution “Filatov institute of eye diseases and tissue therapy AMS of UkrainePhD, Assist. Professor – Artemov A.V. answers the questions:

What is Flaraxin?

Flaraxin is a powerful specific and anti-tumoral interferonogene medicine of vegetarian origin that is produced by unique technology. The acting substance of the medicine consists of vegetarian polyphenol compounds and microcomponents of potassium and iodine. Flaraxin is a lyophilized powder of yellow-brown color, well dissolved in physiological solution of NaCl-0,9% and water.

Who should use FLARAXIN?

Flaraxin should be used for all clinic-morphological forms of malignant neoplasms, at all stages of cancer process, non-malignant neoplasms, under viral, inflectional diseases, accompanied with development of secondary immunodeficiency, inertial viral infections of CNS, diseases that are characterized by the development of autoimmune aggression.

What is known about mechanism of Flaraxin action?

Flaraxin has strictly expressed specific activity to oncological proteins in organism, causes their micro-denatured changes in tumor cells that causing their death with further elimination. Besides specific anti-tumoral effect of Flaraxin has an ability to activate production of endogenous interferon and the tumoral necrosis factor (TNF) in organism, Flaraxin able to support high concentration of interferon during 72 hours after injection. This phenomenon provides wide participation of the immune system in the fight against tumoral structures.

What advantages has Flaraxin in comparison with traditional methods applied in oncology?

The known treatment methods of oncological patients are chemotherapy, radiotherapy and surgery that are accompanied by high immune suppression, closing vicious circle of tumoral process.

The chemotherapy are using medicines, that have a number of reactionally-capable groups that are able to denaturate normal proteins (normal cells) with oncological protein groups, that are explaining its high toxicity for all body.

Flaraxin associated only with tumoral cells (oncological proteins), causing their death and it does not have influence on hematogenesis, on respiratory organs, on excretory and digestive systems, on CNS, on skin and others. Flaraxin is powerful Immunomodulator that does not suppress immune system but vice versa    raises its level of functional activity.

Could be used Flaraxin in patients with exposed allergy, bronchial asthma?

Yes. Flaraxin is able to bound and excrete from the body the circulating immune complexes (CIC). Plasmapheresis is comparable with the ability of Flaraxin to remove CIC out of the body. The application of Flaraxin in patients that are suffering from allergic diseases, bronchial asthma essentially improves the state of patients of this category.

What is the advantage of FLARAXIN treatment of infectious diseases in comparison with interferon groups?

The injections of interferon (including those received by recombination) can give good clinical effect. But this therapy is passive, substitutive, that is giving already prepared interferon and as result the production of own interferon by the body will be reduced. Developed countries starts to use medicines that are able to stimulate production of endogen (personal) interferon and it’s essentially have influence on price of treatment methods as well as their effectiveness. Flaraxin is well combined with other preparations (antibiotics, sulfanilamides) and can be used in mono- and complex therapy.

What is the dosage, ways and methods of FLARAXIN treatment exists?

Flaraxin is produced in tree medical forms: а) lyophilized powder for intravenous injections 150 and 75 mg in glass vials; b) Cones with flaraxin for rectal and vaginal application with 75mg of active substance by 10 cones in box; c) Tablets with Flaraxin for oral application with 25mg of active substance by 40 tablets in plastic container; d) Capsules with Flaraxin for oral application with 150mg of active substance by 10 capsules in blister and by 30 capsules in plastic container;  e) Ointment (balm) with flaraxin 1500mg 40g in plastic container.

The application of Flaraxin in the dose 2 mg/kg for the patient is clinically confirmed. Whereas of absolute Flaraxin non-toxicity the twice- or thrice rising of the dosage does not have negative influence on the body.

Normally Flaraxin is administered as 16 intravenous infusions for one course of the treatment. The injections of the Flaraxin can be done persistently (16 days, one injection a day) with 10-14 days break between the courses or it can be done by two half-courses each 8 days and then 5-7 days break and again half-course 8 days by one injection a day. The break between the full treatment courses should be 10-14 days. 

It can be applicable with Cones, Capsules, tablets or ointment of Flaraxin rectally, vaginally, orally or externally with aim to have local influence on tumors.  The application of Cones, Capsules, Tablets, Ointment is clinically justified under insufficiently exposed venous net or phlebitis, developed as a result of chemotherapy application.

What are side effects can be expected during Flaraxin application?

During application of Flaraxin the allergic reaction can be marked very seldom, mainly it’s related with individual intolerance to iodine containing medicines. During treatment of oncological patients the light pain can appear in the main place of tumoral nod or metastases, more rarely the rise of body temperature up to subfebrile indices can be marked (37,0 – 38,5°С) as a response reaction of the organism on entering of tumoral cells decay products into the blood.


The efficiency of the Flaraxin is confirmed by :

STATE INSTITUTION “INSTITUTE OF PHARMACOLOGY AND TOXICOLOGY OF MEDICAL ACADEMY OF SCIENCE OF UKRAINE  

Address: 14 Ezhena Potie str., c. Kyiv, 01000, Ukraine 

Tel: +38(044) 456-42-56, 456-80-12, 456-98-78

Web-site: http://www.pharm-tox.org.ua    

Head of Department of Biochemical Pharmacology, corresponding member of the Academy of Medical Sciences of Ukraine, Honored Worker of Science and Technology, MD, professor - Y.I. Gubskiy;


ONCOLOGY DEPARTMENT OF MEDICAL FACULTY#2 OF BOGOMOLETS NATIONAL MEDICAL UNIVERSITY 

Address: Verkhovynna str. 69, Kyiv, Ukraine, 

Tel:+38(044)450-82-32 ; 

Associate Professor, PhD -I.P.Loboda;

Corresponding member of the Academy of the Medical Science of Ukraine, elected 05.04.1993, specializing in pharmacology, Corresponding Member of NAS of Ukraine (1991), MD (1973), Professor (1976), Honored Worker of Science of Ukraine (1999), laureate of the State Prize of Ukraine (1986), Academician of the New York Academy of Sciences (1994), Academician of the Academy of Higher Education (1995), director of the Kiev Research Institute of Pharmacology and Toxicology (1987, 1991), Head of the Pharmacology Department of Clinical Pharmacology Exchange of Bogomolets National Medical University of Ministry of Health of Ukraine (1972 till now) - J.S.Chekman;


DEPARTMENT OF HEAD AND NECK TUMORS OF STATE INSTITUTION "NATIONAL CANCER INSTITUTE" OF UKRAINE. 
Before Kyiv Research Institute of X-ray Radiology and Oncology of the USSR Ministry of Health, 

Address: Kyiv, 03022, Lomonosova st., 33/43,

Tel. +38 (044) 259-01-86,

Doctor of Medical Sciences, Professor, Honored Scientist of Ukraine  - V.S.Protsyk.


ONCOLOGY DEPARTMENT OF STATE INSTITUTION “CRIMEA MEDICAL UNIVERSITY NAMED AFTER S.I.GEORGIEVSKY” 

Address:  Crimean Republican Oncology Dispensary , Bespalova Str. 49а,

Tel.: +38(0652)63-89-78, 

Web-site: http://www.csmu.edu.ua/site/page/show/docid/169963

Head of the Oncology Department, surgeon, oncologist, Professor Emeritus Doctor and Honorary Doer of Science and Technology of Ukraine and the Autonomous Republic of Crimea, Honorary Citizen of the Autonomous Republic of Crimea, MD, Professor -  Efetov V.M.


DEPARTMENT OF INTERFERON AND IMMUNOMODULATORS OF THE D.K.ZABOLOTNY INSTITUTE OF MICROBIOLOGY AND VIROLOGY OF NASU; 

Address: Akademik Zabolotny st., 154, 03680, Kyiv, Ukraine,

Tel: +38(044)526-11-79. 

Head of the Department, Corr. NASU, Doctor of Biology, Professor -Mykola Spivak. 


DEPARTMENT OF BIOCHEMISTRY OF TUMOR GROWTH OF R.E.KAVETSKY INSTITUTE OF EXPERIMENTAL PATHOLOGY, ONCOLOGY AND RADIOBIOLOGY OF NATIONAL ACADEMY OF SCIENCE OF UKRAINE 

Address: Vasylkivska st.,45, Kyiv, 03022, Ukraine,

Tel: +38(044)259-01-83.

Chief of the Department of Biochemistry of tumor growth, M.D., professor –Shliakhovenko V.O.


STATE INSTITUTION “THE FILATOV INSTITUTE OF EYE DISEASES AND TISSUE THERAPY AMS OF UKRAINE”, 

Address: Ukraine, 65061, Odessa, Frantsuzkyi Boulevard, 49/51. 
E-mail: art_onkol@ukr.net
Head of the Laboratory of Pathomorphology and preservation of donor tissue PhD, Assist. Professor – Artemov A.V.

кандидат медицинских наук Артемов Александр Валентинович

WHAT DOCTORS DON’T TELL YOU?!

We like to thank and highlight The Dr.Rath Health Foundation for their extraordinary work on health, peace and social justice. About author: Dr. Matthias Rath has become a voice of conscience exposing the global conquest plans of thechemical/pharmaceutical Cartel in our time. Attacked by Cartel media the world over, Dr. Rath and his Foundation have received prestigous awards for civil courage. The ‘Relay of Life’ Award – presented by survivors of the KZ Auschwitz and other Nazi concentration camps was conferred with the mandate: ‘Never again!’

On 14 th June 2003 te Dr. Rath Health Foundation submitted a complaint of genocide and other crimes against humanity to the International Criminal Court in The Hague . To date, no action has been taken by this United Nations court, despite the overwhelming evidence against the accused.